Ország: Ausztrália
Nyelv: angol
Forrás: Department of Health (Therapeutic Goods Administration)
Prednisone
Mundipharma Pty Ltd
Medicine Registered
LODOTRA ® MODIFIED RELEASE TABLETS 1 LODOTRA ® _MODIFIED RELEASE TABLETS _ _Prednisone _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about LODOTRA ® modified release tablets. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking this medicine against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT LODOTRA ® MODIFIED RELEASE TABLETS ARE TAKEN FOR LODOTRA ® modified release tablets contain a medicine called prednisone, and act through a delayed release mechanism. Prednisone belongs to a group of medicines called corticosteroids. LODOTRA ® modified release tablets are used to treat moderate to severe, active rheumatoid arthritis, particularly when accompanied by stiffness of the joints in the morning. Corticosteroids have an anti- inflammatory action, and are used to reduce the pain, swelling, redness and heat in the affected joints. LODOTRA ® modified release tablets are designed to release prednisone approximately four hours after being swallowed. When taken at bedtime, they produce an improvement in the joint stiffness and other symptoms usually experienced upon wakening. Your doctor, however, may prescribe LODOTRA ® modified release tablets for another purpose. Ask your doctor if you have any questions about why this medicine has been prescribed for you. This medicine is only available with a doctor's prescription. BEFORE YOU TAKE IT _WHEN YOU Olvassa el a teljes dokumentumot
LODOTRA ® modified release tablets PI (September 2012) Page 1 of 19 mfplodot10912 PRODUCT INFORMATION LODOTRA ® 1 MG, 2 MG AND 5 MG MODIFIED RELEASE TABLETS NAME OF THE MEDICINE prednisone DESCRIPTION Prednisone is an odourless, white crystalline powder, which is practically insoluble in water, slightly soluble in alcohol and methylene chloride. The melting point is 233-235 o C. The octanol-water partition coefficient (log P) is 1.46. The chemical name is 17α,21-dihydroxypregna-1,4-diene-3,11,20-trione, and its molecular weight is 358.4. The molecular formula is C 21 H 26 O 5 . The structural formula is: CAS No: 53-03-2 LODOTRA ® modified release tablet: The formulation has been designed as a timed-release tablet. The core contains lactose, silica - colloidal anhydrous, croscarmellose sodium, magnesium stearate, povidone and iron oxide red CI77491. The shell contains silica - colloidal anhydrous, calcium hydrogen phosphate, glyceryl behenate, magnesium stearate, povidone and iron oxide yellow CI77492. PHARMACOLOGY ACTIONS The pharmacotherapeutic group is ‘glucocorticoids’ and the ATC code is H02AB07. Prednisone is a non-fluorinated glucocorticoid for systemic therapy, which has a dose- dependent effect on the metabolism in almost all tissues. Under physiological conditions, these effects are central to maintaining homoeostasis of the organism at rest and under stress, and for controlling the actions of the immune system. Prednisone has the same chemical relationship to prednisolone as cortisone has to hydrocortisone. The mechanism of action of corticostero Olvassa el a teljes dokumentumot